Guideline Summary for Ulcerative Colitis with Pancolitis

Disease Severity Stratification

• Patients presenting with bloody diarrhea, urgency, and tenesmus but without systemic symptoms should be classified as mild‑to‑moderate and start aminosalicylate therapy. American Society of Gastroenterology recommendation. 1
• Patients who require corticosteroids at presentation or who have a high risk of colectomy should be classified as moderate‑to‑severe and considered for early advanced therapy. American Society of Gastroenterology recommendation. 2
• Patients meeting Truelove and Witts’ criteria (≥6 bloody stools/day, fever, tachycardia, anemia, or markedly elevated inflammatory markers) are defined as acute severe disease and require immediate hospitalization. American Society of Gastroenterology and British Society of Gastroenterology guidance. [1][2]

First‑Line Therapy for Mild‑to‑Moderate Pancolitis

• Combination oral mesalazine (2–4 g/day) plus topical mesalazine enema (1 g/day) is superior to monotherapy for inducing remission. British Society of Gastroenterology guideline (strong recommendation). 1
• Oral + rectal 5‑ASA regimens achieve higher remission rates than either route alone. British Society of Gastroenterology guideline (strong recommendation). 1
• Topical mesalazine is more effective than topical corticosteroids and should be the first‑line rectal agent. British Society of Gastroenterology guideline (strong recommendation). 1
• After remission, maintain the induction dose for at least 4 weeks to prolong remission and lower relapse frequency. European Crohn’s & Colitis Organisation evidence (moderate quality). 3
• Sulfasalazine (2–4 g/day) is associated with higher adverse‑event rates and should be reserved for selected patients (e.g., those with reactive arthropathy). British Society of Gastroenterology guideline (weak recommendation). 1

Escalation to Systemic Corticosteroids

• If no clinical response to optimized combination 5‑ASA within 2–4 weeks, initiate oral prednisolone 40 mg/day. British Society of Gastroenterology guideline (strong recommendation). 1
• Continue topical mesalazine as adjunctive therapy while on systemic steroids to maximize local anti‑inflammatory effect. British Society of Gastroenterology guideline (strong recommendation). 1
• Taper prednisolone gradually over 8 weeks; rapid taper increases early relapse risk. British Society of Gastroenterology guideline (strong recommendation). 1
• Systemic corticosteroids must never be used for long‑term maintenance because of significant adverse effects. American Society of Gastroenterology guideline (strong recommendation). 2

Management of Hospitalized Acute Severe Pancolitis

• Administer intravenous methylprednisolone 40–60 mg/day; doses >60 mg provide no additional benefit. American Society of Gastroenterology guideline (strong recommendation). 2
• Do not postpone corticosteroid therapy while awaiting stool microbiology results, although infectious causes must be excluded. British Society of Gastroenterology guideline (strong recommendation). 1
• Provide intravenous fluid and electrolyte replacement to correct dehydration. British Society of Gastroenterology guideline (strong recommendation). 1
• Use subcutaneous heparin prophylaxis to reduce thromboembolic risk. British Society of Gastroenterology guideline (strong recommendation). 1
• Transfuse packed red cells to maintain hemoglobin >10 g/dL. British Society of Gastroenterology guideline (strong recommendation). 1
• Monitor vital signs four times daily (more frequently if deteriorating). British Society of Gastroenterology guideline (strong recommendation). 1
• Record stool frequency, consistency, and blood presence daily on a stool chart. British Society of Gastroenterology guideline (strong recommendation). 1
• Perform complete blood count, inflammatory markers (CRP/ESR), electrolytes, albumin, and liver function tests every 24–48 hours. British Society of Gastroenterology guideline (strong recommendation). 1
• Obtain daily abdominal radiographs if colonic dilatation (transverse colon >5.5 cm) was present at admission. British Society of Gastroenterology guideline (strong recommendation). 1
• Ensure joint medical and surgical management with a colorectal surgeon. British Society of Gastroenterology guideline (strong recommendation). 1
• Assess response to IV corticosteroids after 3–5 days; lack of response by day 7 warrants escalation to rescue therapy or colectomy. American Society of Gastroenterology guideline (strong recommendation). 2
• Avoid adjunctive antibiotics in the absence of documented infection (conditional recommendation, very low‑quality evidence). American Society of Gastroenterology guideline. 2

Maintenance Therapy Strategy

• After achieving remission with 5‑ASA, continue oral mesalazine ≥2 g/day lifelong. European Crohn’s & Colitis Organisation evidence (moderate quality). 3
• Discontinue 5‑ASA in patients who have escalated to biologic or immunomodulator therapy after failing aminosalicylates, as no additional benefit is observed. American Society of Gastroenterology guideline (strong recommendation). 2
• Lifelong maintenance therapy is recommended for all patients with pancolitis because extensive disease carries a higher relapse risk than distal disease. European Crohn’s & Colitis Organisation evidence (moderate quality). 3

Key Pitfalls to Avoid

• Do not continue systemic corticosteroids beyond 8 weeks for maintenance due to lack of efficacy and increased adverse effects. American Society of Gastroenterology guideline (strong recommendation). 2
• Do not delay escalation to advanced therapy in patients who fail corticosteroids within 2 weeks or who have high‑risk features. American Society of Gastroenterology guideline (strong recommendation). 2
• Do not maintain 5‑ASA after transitioning to biologic therapy unless residual proctitis is present. American Society of Gastroenterology guideline (strong recommendation). 2
• Do not use intravenous corticosteroid doses >60 mg methylprednisolone equivalent in hospitalized patients, as higher doses provide no additional benefit. American Society of Gastroenterology guideline (strong recommendation). 2

Celecoxib Use in Ulcerative Colitis Patients – Safety and Clinical Guidance

Guideline Recommendations for NSAID Use in Inflammatory Bowel Disease

• The American College of Rheumatology and Spondylitis Association guidelines note that evidence is limited for preferring celecoxib over other NSAIDs in patients with inflammatory bowel disease, but short‑course celecoxib may pose less potential harm than traditional NSAIDs (low‑quality evidence). 4
• The same guidelines state that no specific NSAID is recommended to reduce the risk of IBD symptom worsening; however, celecoxib is the most studied NSAID in this context (very low‑quality evidence). 4
• For patients who have both active ulcerative colitis and spondyloarthritis, the guidelines strongly recommend TNF‑inhibitor monoclonal antibodies (e.g., infliximab, adalimumab) rather than etanercept, because these agents address both the intestinal inflammation and the arthritis, eliminating the need for NSAIDs. 4

Safety Profile of Short‑Term Celecoxib in Quiescent Ulcerative Colitis

• In ulcerative colitis patients who are in remission and require NSAID therapy, celecoxib 200 mg twice daily is suggested as the preferred NSAID, with an initial treatment duration limited to ≤2 weeks and close monitoring for disease exacerbation (e.g., increased stool frequency, rectal bleeding, abdominal pain). 5
• Celecoxib retains the cardiovascular risks typical of COX‑2 inhibitors, including possible elevation of blood pressure and a heightened risk of thrombotic events; these risks must be weighed against any analgesic benefit. 5
• The gastrointestinal protective advantage of celecoxib is lost when patients are concurrently taking low‑dose aspirin, eliminating its relative safety benefit for the gut. 5

Recommendations for Active or Moderate‑Severe Ulcerative Colitis

• Clinical guidance advises avoiding all NSAIDs, including celecoxib, in patients with active or moderate‑severe ulcerative colitis, and to manage pain with alternatives such as acetaminophen, topical agents, or physical therapy. 6
• In ulcerative colitis patients with a history of prior ulcer complications, celecoxib is associated with an estimated recurrent gastrointestinal bleeding rate of approximately 4.9 % per year, indicating a high‑risk profile for this subgroup. 6

Ulcerative Colitis Treatment Guidelines

Initial Treatment

• For mild to moderate ulcerative colitis, the American Gastroenterological Association recommends starting with 5-aminosalicylic acid (5-ASA) therapy tailored to disease location: rectal 5-ASA 1g daily for proctitis, or oral 5-ASA 2.0-4.8g daily for disease beyond the rectum, with combination oral and rectal therapy offering superior remission rates 7, 8
• The European Crohn’s and Colitis Organisation suggests that rectal 5-ASA is superior to rectal corticosteroids for inducing remission 8
• Oral 5-ASA 2.0-4.8g daily is recommended as first-line therapy for left-sided or extensive disease, with the option to enhance efficacy by combining with rectal 5-ASA (enemas ≥1g daily) 7, 8

Treatment Algorithm Based on Disease Severity and Extent

• For moderate to severe active disease, the American Gastroenterological Association recommends oral corticosteroids as first-line therapy, with prednisolone 40mg daily being the recommended dose 9, 10
• The British Society of Gastroenterology suggests combining corticosteroids with 5-ASA therapy 9
• For patients at high risk of colectomy or those failing corticosteroids within 2 weeks, the American Gastroenterological Association recommends initiating advanced therapy early, with infliximab or vedolizumab being preferred over adalimumab or golimumab based on network meta-analysis 11, 12, 13

Maintenance Strategy

• The American Gastroenterological Association recommends continuing the same agent that successfully induced remission, with 5-ASA-induced remission requiring continuation of oral 5-ASA ≥2g daily 7, 8
• For biologic-induced remission, the European Crohn’s and Colitis Organisation suggests continuing the same biologic 11, 12
• Patients in remission on biologics/immunomodulators may discontinue 5-ASA, as there is no added benefit 11, 12, 14

Treatment Goals

• The modern treatment target has shifted from symptom control to achieving complete remission assessed biochemically, endoscopically, and histologically to prevent long-term complications, as recommended by the British Society of Gastroenterology 9, 10